CD274 and urinary bladder carcinoma: Due to the efficacy of immunotherapy against bladder cancer and the low response rate of platinum NAC, the PD-1/PD-L1 inhibitors have been incorporated in the neoadjuvant immunotherapy for MIBC along with radiotherapy and chemotherapy [39].